An entrepreneur turned venture capitalist, Mr. Thorp is Co-Founder and General Partner of Hatteras Venture Partners, a venture capital partnership that manages over $700 million across six vintages. Since 1995, he has co-founded eight companies in the life science arena. Mr. Thorp has led investments and numerous strategic transaction processes in a range of life science companies, including biopharmaceuticals, medical devices, diagnostics and research informatics. These companies include: ArtusLabs, Asthmatx, Inc., Clearside Biomedical, Embrella, G1 Therapeutics, Kymera Therapeutics, Lysosomal Therapeutics, Inc., PhaseBio Pharmaceuticals and Synthematix, Inc. Mr. Thorp serves as Chairman of PhaseBio Pharmaceuticals Board of Directors and is on the boards of Clearside, GeneCentric Therapeutics, Seaport Diagnostics, StrideBio and Vigil Neuroscience. He is also on the Strategic and Scientific Advisory Board of Brii Biosciences. Mr. Thorp serves on the Chancellor’s Philanthropic Committee at University of North Carolina (UNC) at Chapel Hill, the Board of Visitors of the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill and on the board of the North Carolina School of Science and Mathematics Foundation. He holds a M.P.P. from Harvard University and a B.A. in Mathematics and Art History from UNC-Chapel Hill.